Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    FDA_Warning_Letters, Import_Alerts_&_EU_Non-Compliances_in_2019
    X

    Find Oncology Drugs in Phase I Clinical Development in ISRAEL

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type

              Companies

              Compugen

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              ISRAEL Israel

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              WRIB

              Participation Not Confirmed

              Update your events

              Compugen Announces Updated Clinical Data from Ongoing COM701 Phase 1 Study

              Contact the Supplier

              Lead Product(s): COM701

              Therapeutic Area: Oncology

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 09, 2020

              Details:

              COM701 demonstrates preliminary antitumor activity with confirmed partial responses as monotherapy in a patient with primary peritoneal cancer and in combination with Opdivo in MSS-CRC.

              Compugen

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              ISRAEL Israel

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              WRIB

              Participation Not Confirmed

              Update your events

              Compugen Announces Phase 1/2 Triple Combination Study to Evaluate COM701 in Combination With Bristol-Myers Squibb's Opdivo®

              Contact the Supplier

              Lead Product(s): COM701,Nivolumab,BMS-986207

              Therapeutic Area: Oncology

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 20, 2020

              Details:

              Triple combination study intended to evaluate Compugen's PVRIG pathway discovery and DNAM axis hypothesis in patients with advanced solid tumors

              NeoTX Therapeutics

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              ISRAEL Israel

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              WRIB

              Participation Not Confirmed

              Update your events

              Israeli biotech NeoTX lands $45M series C for combo I-O cancer trials

              Contact the Supplier

              Lead Product(s): Naptumomab estafenatox,Durvalumab

              Therapeutic Area: Oncology

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Undisclosed

              Deal Size: $45.0 million Upfront Cash: Undisclosed

              Deal Type: Series C Financing February 19, 2020

              Details:

              The company plans to complete the dose escalation phase of the Phase 1b trial of naptumomab estafenatox in combination with durvalumab and continue to develop our patented STR platform.

              Kitov Pharma

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              ISRAEL Israel

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              WRIB

              Participation Not Confirmed

              Update your events

              Kitov Pharma Receives Issue Notification for a U.S. Patent

              Contact the Supplier

              Lead Product(s): CM-24

              Therapeutic Area: Oncology

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 03, 2020

              Details:

              Recognition from the USPTO validates the unique profile of Kitov’s CM-24. The mechanism of action of CM-24 results in an enhanced cytotoxic activity of the immune system cells.

              LipoMedix

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              ISRAEL Israel

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              WRIB

              Participation Not Confirmed

              Update your events

              LipoMedix Announces Publication of Positive Phase 1 Data for Promitil® (PL-MLP) in Research Journal Investigational New Drugs

              Contact the Supplier

              Lead Product(s): Promitil,Capecitabine,Bevacizumab

              Therapeutic Area: Oncology

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 23, 2020

              Details:

              Study authors found that Promitil may be a useful agent in patients with metastatic colorectal cancer (CRC).

              Kitov Pharma

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              ISRAEL Israel

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              WRIB

              Participation Not Confirmed

              Update your events

              Kitov Pharma Announces Closing of FameWave Acquisition

              Contact the Supplier

              Lead Product(s): CM-24,Nivolumab

              Therapeutic Area: Oncology

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Kitov Pharma

              Deal Size: $13.5 million Upfront Cash: $13.5 million

              Deal Type: Acquisition January 08, 2020

              Details:

              The acquisition strengthens Kitov’s oncology pipeline with the addition of novel checkpoint inhibitor, CM-24. Kitov intends to initiate a phase 1b/2a clinical trial of CM-24 + nivolumab.

              PharmaCompass__DigitalAd